BFM
FPRX

Boothbay Fund Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Boothbay Fund Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14,586
Closed -$69K – 1546
2020
Q3 		$69K Sell
14,586
-4,419
-23% -$22.4K ﹤0.01% 994
2020
Q2 		$116K Buy
19,005
+905
+5% +$3.73K 0.01% 866
2020
Q1 		$41K Buy
+18,100
New +$76.8K ﹤0.01% 794

Other funds holding FPRX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's FPRX Position: Q4 2020 in Review

Boothbay Fund Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 14,586 shares — an estimated $69K sold.

Boothbay Fund Management first reported a position in FPRX in Q1 2020 and held it in 3 quarters. The position peaked at $116K in Q2 2020. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

  • Boothbay Fund Management reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 14,586 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $69K.
  • Boothbay Fund Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2020 and held it in 3 quarters.
  • Boothbay Fund Management's Five Prime Therapeutics, Inc. position peaked at $116K in Q2 2020.
  • 125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on Boothbay Fund Management's 13F filing for Q4 2020, filed 12 Feb 2021.